NasdaqGS - Nasdaq Real Time Price USD

IDEXX Laboratories, Inc. (IDXX)

551.21 -24.77 (-4.30%)
At close: October 30 at 4:00:01 PM EDT
538.70 -12.51 (-2.27%)
After hours: October 30 at 7:31:22 PM EDT
Trade IDXX on Coinbase
IDXX Q3 2026 earnings call
November 2, 2026 at 8:30 AM EST
Chart Range Bar
Loading chart for IDXX

What's happening with IDXX?

1h ago
Powered by Yahoo Scout

IDEXX Laboratories faces a near-term earnings catalyst on November 2, 2026, with analysts expecting higher revenue and earnings. Valuation remains debated after a recent rally, while recurring diagnostics revenue and product expansion support the growth case. Shares are down 4.30% in the current regular session, according to the authoritative market data.

Powered by Yahoo Scout
  • Previous Close 575.98
  • Open 583.75
  • Bid 571.58 x 100
  • Ask 543.56 x 200
  • Day's Range 540.61 - 586.00
  • 52 Week Range 500.61 - 769.98
  • Volume 1,121,502
  • Avg. Volume 553,104
  • Market Cap (intraday) 43.425B
  • Beta (5Y Monthly) 1.55
  • PE Ratio (TTM) 38.74
  • EPS (TTM) 14.23
  • Earnings Date Nov 2, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 694.42
  • Morningstar Rating
    Rating available with Stock Picks access

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

www.idexx.com

11,000

Full Time Employees

December 31

Fiscal Year Ends

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

IDXX
18.52%
S&P 500 (^GSPC)
10.73%

1-Year Return

IDXX
12.30%
S&P 500 (^GSPC)
11.11%

3-Year Return

IDXX
39.06%
S&P 500 (^GSPC)
81.91%

5-Year Return

IDXX
17.25%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized
 

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 1.22B
Earnings 338.41M
Profit Margin 27.82%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
200M
400M
600M
800M
1B
1B
23.0%
24.0%
25.0%
26.0%
27.0%
 

Analyst Insights

View More

Top Analyst

Morgan Stanley
57/100
Latest Rating
Overweight
 

Analyst Price Targets

470.00 Low
694.42 Average
551.21 Current
805.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Latest Rating

Date 10/27/2026
Analyst UBS
Rating Action Maintains
Rating Neutral
Price Action Lowers
Price Target 670 -> 627
 

Statistics

View More

Valuation Measures

Annual
As of 10/30/2026
  • Market Cap

    43.42B

  • Enterprise Value

    44.32B

  • Trailing P/E

    38.74

  • Forward P/E

    33.29

  • PEG Ratio (current)

    3.48

  • Price/Sales (ttm)

    9.70

  • Price/Book (mrq)

    27.06

  • Enterprise Value/Revenue

    9.73

  • Enterprise Value/EBITDA

    27.46

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    25.03%

  • Return on Assets (ttm)

    27.09%

  • Return on Equity (ttm)

    74.21%

  • Revenue (ttm)

    4.55B

  • Net Income Avi to Common (ttm)

    1.14B

  • Diluted EPS (ttm)

    14.23

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    196.93M

  • Total Debt/Equity (mrq)

    67.97%

  • Levered Free Cash Flow (ttm)

    909.37M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

551.21 Current
 

Dividend Score

0 Low
Sector Avg.
100 High
 

Hiring Score

0 Low
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
Sector Avg.
100 High
 

Research Reports

View More
  • Raising target price to $617.00

    IDEXX LABORATORIES INC has an Investment Rating of BUY; a target price of $617.000000; an Industry Subrating of Medium; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Medium.

     
  • Raising target price to $614.00

    IDEXX LABORATORIES INC has an Investment Rating of BUY; a target price of $614.000000; an Industry Subrating of Medium; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Medium.

     
  • Raising target price to $572.00

    IDEXX LABORATORIES INC has an Investment Rating of BUY; a target price of $572.000000; an Industry Subrating of Medium; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Medium.

     
  • Lowering target price to $567.00

    IDEXX LABORATORIES INC has an Investment Rating of BUY; a target price of $567.000000; an Industry Subrating of Medium; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Medium.

     

People Also Watch